(updates survey details in second paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P. (Bloomberg) -- The next leg higher in long-term Treasury yields may come from what’s known as real rates, one of the bond market’s purest reads on the growth outlook.A burst of strong economic readings -- a mammoth job creation figure Friday and now a report from the Institute for Supply Management showing record growth in service industries -- is fueling bets that expectations for growth, not inflation, will dominate the narrative in Treasuries.That’s an important distinction because while higher real rates, which strip out inflation, suggest investors see the economic rebound from the pandemic gaining steam, a persistent rise may hurt other assets, including stocks. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced an expanded infectious disease pandemic development program, including novel vaccines for COVID-19 and universal influenza, in addition to … More insight into officials’ plans for asset purchases may come Wednesday with the release of the minutes from the central bank’s March gathering.Some investors aren’t too concerned about the climb in real rates.If that’s what’s driving the increase in nominal yields, “that’s a positive reason for rates to be moving up,” Karissa McDonough, chief fixed-income strategist at Peoples United Advisors Inc., said in a Bloomberg TV interview. That has caused investors to turn more bearish on the precious metal -- holdings in bullion-backed exchange-traded funds have dropped to the lowest since May, while hedge funds cut net bullish gold bets to a three-week low last week.“Gold is likely to face an uphill climb -- the global economy is recovering fast,” said Howie Lee, an economist at Oversea-Chinese Banking Corp.Spot gold was up 0.1% at $1,726.75 an ounce at 2:45 p.m. in New York. PDS Biotechnology Corporation (NASDAQ: PDSB) NTN Buzztime Inc. Atossa Therapeutics Inc. (NASDAQ: ATOS) Novan Inc. This is a real threat to patients with advanced COVID-19. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. The annualized rate of $1.24 gives a yield of 9%. Fidus’ shares are selling for $15.70 and their $17.17 average price target indicates a 9% upside potential from that level. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. These companies generally inhabit the middle-market finance sector, where they make available capital for acquisitions, recapitalizations, and general operations to mid-market companies that don’t necessarily have access to other sources of credit. Tesla’s first-quarter delivery numbers settled the question of whether demand for electric vehicles would strengthen and reach critical mass. The company that Fidus has invested in are valued between $10 million and $150 million. (Update with interviews with Sarcos and Rotor executives. “We believe that pairing PDS Biotech’s Versamune® T-cell activating vaccine technology with Farmacore’s recombinant SARS-CoV-2 protein will allow us to quickly assess the efficacy of Versamune®-CoV-2FC to potentially reduce the continuing spread of COVID-19 infections.”. “PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune®-based COVID-19 vaccine into the clinic,” said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.“ The preclinical results demonstrate the vaccine’s potential to induce a broad range of robust anti SARS-CoV-2 immune responses. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. We applaud Farmacore Biotechnology and Blanver Farmoquímica for reaching this important milestone and look forward to the results of the planned human clinical trials and hopefully a rapid advancement towards commercialization of the product. Notably, the protein in this fully synthetic vaccine includes conserved and non-mutating regions of the virus. PDS0203 pairs the … PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being jointly developed for Latin America by a consortium that includes PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica. “When you think about our children... they're going to be very comfortable transacting in Ethereum or Bitcoin, and I’ve got to get my clients ready for that,” he said. Chairman of biotech firm selling Covid tests admits it’s a hoax part 1 “There is utterly unfounded public hysteria driven by the media and politicians. An expected reduction in Fed accommodation amid an improving economic outlook could push the 10-year TIPS yield positive before asset purchases start to taper.”-- Ira. Benzinga does not provide investment advice. The pre-IMPD package for the Phase 1/2 trial is currently under review by Anvisa and the trial is anticipated to begin by Q2/3 2021. PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and P... Read More Mar 17, 2021. PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. “I predicted Ethereum has good fundamentals and will grow, but I’m in an institutionalist sort of business. As the license holder of PDS0203 in Latin America, Farmacore Biotechnology will continue to lead the regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization, to conduct clinical trials in Brazil. Why It Matters: In recent months, Ethereum has risen in popularity, and price, after its use cases extended beyond DeFi (decentralized finance) into the realm of NFTs (non-fungible tokens). It’s also possible that it does a little of both. The vaccine has demonstrated strong potential in preclinical studies to efficiently promote the induction of killer (CD8+) and helper (CD4+) T-cells that recognize and induce immune responses against such non-mutating regions of the virus. In addition to this regular payment, Fidus also declared a special dividend of 7 cents per share, nearly double the 4-cent special payment made in the previous quarter. U.S. Treasury Secretary Janet Yellen said on Monday that she is working with G20 countries to agree on a global corporate minimum tax rate and pledged that restoring U.S. multilateral leadership would strengthen the global economy and advance U.S. interests. Also up was investment income, which at $221.3 million for the quarter was up 9% year-over-year. Brazilian government to provide initial funding support to progress development of Versamune ®-based vaccine to prevent COVID-19 infection. PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an Award of up to Approximately US$60 million . Scaramucci: Bitcoin Is The Apex Predator, But Ethereum Will Be The Actual Store Of Value. “If they have a 1, 2, or 3% position they're going to look at us as fiduciaries and think they were very well served.” See more from BenzingaClick here for options trades from BenzingaCoinbase Employees Exchange NFT Wedding Rings On Ethereum Blockchain During CeremonyAnalysts Suggest 'Silent Crash' May Be Underway As NFT Prices Floors Plummet© 2021 Benzinga.com. Dr. Scangos explains what this role means and why collaboration across the private, public and NGO sectors is vital in combating Coronavirus. More than a dozen are not excluding the benefits from state taxes. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. In 2019, ORCC paid out for 80 cent special dividends, along with the regular dividend payments. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. The rapidly increasing number of SARS-CoV-2 mutations highlights the need for novel, second generation vaccines capable of generating both killer and helper T-cells that can recognize and attack conserved and non-mutating regions of the virus. PDS Biotech is in discussions with other governmental and non-governmental agencies regarding additional funding for a COVID-19 vaccine. This company, like Owl Rock, offers capital access to smaller firms, including access to debt solutions. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101 and PDS0203 ; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and PDS0203 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to the COVID-19 pandemic. While it’s early for the Fed to declare victory on its goals, the strong data should spark the central bank to open the door to tapering discussions, likely at their June meeting -- with an announcement in the final quarter of the year, they say.Data from other major economies have also been encouraging. Schwere Covid-19-Verläufe können so verhindert werden. The growing interest in COVID-related stocks has this one on watch as investors shift focus from vaccines to preventative treatments. It is very important to do your own analysis before making any investment. The crises of the past year – the COVID pandemic, the social lockdowns, the economic shock – are on the wane, and that’s good. Mar 11, 2021 PDS Biotechnology Shares Jump 70% on Covid-19 Vaccine Funding in Brazil Dow Jones Newswires; Mar 11, 2021 PDS Biotechnology Vaccine Consortium Gets … This type of coronavirus has not been seen before. The second-largest cryptocurrency by market cap has garnered support from high-profile investors, including Mark Cuban, who recently revealed his bullish stance on Ethereum, calling it a “hotbed of continuous innovation”. Versamune®-CoV-2FC (PDS0204) is a COVID-19 vaccine candidate that combines the immune-activating Versamune® platform with a Farmacore-developed recombinant fusion protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) recognizable by our immune system (antigen). in Mumbai, who expects a status quo.Here’s what to watch for in the MPC decision to be announced by Governor Shaktikanta Das in Mumbai on Wednesday morning:Growth ProspectsIn February, the central bank said it expects the economy to expand 10.5% in the year that began April 1 after an estimated 7.7% contraction in the previous 12 months. Connect with the definitive source for global and local news. PDS Biotech (PDSB Stock Report) has been on the radar for months. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and. The dividend yield, however, is the true attraction here (To watch Penn’s track record, click here.) Spot silver, platinum and palladium all fell.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P. Since last April, the stock has gained an impressive 153%. (See FDUS stock analysis on TipRanks) To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Blanver Farmoquímica e Farmacêutica S.A. is a Brazilian company, founded in 1984, focused on R&D, manufacture and sale of innovative medicines and active pharmaceutical ingredients. While Das has indicated there is no immediate threat to that forecast, he could still flag downside risks, given the current surge in virus cases that’s hurting mobility and consumption.Inflation ForecastWith Prime Minister Narendra Modi’s government renewing the central bank’s mandate of keeping inflation between 2%-6% for another five years, policy makers are likely to reiterate that fighting price pressures will be a top priority. Owl Rock’s portfolio consists of investments in 119 companies, totaling $11.3 billion. But those gains could come undone quickly if consumer demand is hit due to curbs on movement, such as those imposed in the capital New Delhi and by the state of Maharashtra, which houses the financial hub of Mumbai and contributes about 15% of the national output.“The current state of affairs will ensure that RBI will not pull back accommodative measures in a hurry,” said Teresa John, economist at Nirmal Bang Equities Pvt. Governor Das has assured investors that RBI will help ease the supply burden by purchasing at least 3 trillion rupees ($41 billion) of bonds through open market purchases, or OMOs, and more durable cash injection to compensate for the withdrawal of a relaxation in a cash reserve ratio.“We expect the RBI to reiterate that surplus liquidity will remain ample to support growth and that the space created by CRR reversal will be offset by OMO purchases of bonds to help bridge the gap between demand-supply of bonds and prevent longer-end bond yields from shooting up excessively in a short period of time,” said Kaushik Das, chief India economist at Deutsche Bank AG. At the time the company announced that it expanded its infectious disease pandemic development program. (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER You are being offered the Janssen COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by … PDS Biotechnology, a clinical stage immunotherapy company, has announced positive results from preclinical testing conducted at the University of Kentucky College of Medicine of its COVID-19 vaccine candidate, PDS0203. The consortium members will work under a mutually agreed work plan to guide the vaccine efficiently through development in compliance with regulatory standards. Markets are rising, and that, as Stoltzfus says, “…in our view likely presents more opportunity than risk for investors who have suitable tolerance for risk and who practice patience.” Taking Stoltzfus’ outlook into consideration, we wanted to take a closer look at two stocks earning a round of applause from Oppenheimer's stock analysts. The funding is being awarded to the COVID-19 vaccine consortium, which includes PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica. Of particular interest to dividend investors, Owl Rock’s board declared a 31-cent per common share dividend for the first quarter. “PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune®-based COVID-19 vaccine into the clinic,” said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.“ The preclinical results demonstrate the vaccine’s potential to induce a broad range of robust anti SARS-CoV-2 immune responses. Press release content from Globe Newswire. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. PDS Biotechnology announced that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to about $60 million to support the clinical development and commercialization of a novel, Versamune-based, second generation COVID-19 … For the full year 2020, the adjusted net income reached $38 million, up from $35.3 million in 2019. Investors appear to be responding to the company announcing that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, … Relatively risky assets could start to suffer with the market signaling that it sees growth getting so strong that it expects the Federal Reserve to start discussing a tapering of its asset purchases as a step toward tightening policy.Ten-year U.S. real yields -- as measured by the rate on inflation-linked Treasuries -- are about minus 0.65%, near the highest since mid-2020 and up from a record low of negative 1.12% in September. The company declared its 1Q21 payment in February, and paid out on March 26. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. (To watch Kotowski’s track record, click here) “The fundamentals [are] stable with debt investments at year-end essentially stable and interest income in line with both the prior quarter and our estimate…. “I think the Fed is happy to see rates increase like this. PDS Biotech Announces Presentation and Panel Participation at the Benzinga Biote... Read More Mar 11, 2021. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support (Bloomberg) -- Gold steadied as investors weighed a better-than-expected U.S. jobs report against a weakening dollar.Employers in the U.S. added the most jobs in seven months in March, as more coronavirus vaccinations and fewer business restrictions bolstered the labor market recovery. GlobeNewswire • June 17, 2020. The post How DeFi Is Minting the Next Class of Millionaires appeared first on Worth. This figure suggests a 15% one-year upside. The Versamune® platform, due to its unique ability to induce both antibody and polyfunctional CD8+ killer and CD4+ helper T-cell responses is being utilized to develop a next generation vaccine that may more effectively prevent COVID-19. It is a technology-based company that conducts research and development of biotechnological products and processes for the human and veterinary sectors. “However, a smaller inflation pick-up may tilt the composition of any yield increases more heavily towards real yields.”Ten-year nominal yields are about 1.7%, holding below the 1.77% level reached March 30, the highest since January 2020. Development and commercialization of novel T-cell activating vaccine to be performed … All rights reserved. It develops innovative biotechnological and immunobiological products and adds value to them in all stages of development, from project design to biomolecule production www.farmacore.com.br. No one, for now, can say for sure that the so-called family office's billions in investment losses won't spread. Fuel and food prices, which make up more than 50% of the consumer price index, represent the biggest problem for rate setters, given their ripple effect on inflationary expectations and underlying price pressures.India is among the few emerging markets in Asia where inflation is above the midpoint of its target band, due largely to food prices that are rising after a brief drop. PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an … In joining forces with our partner PDS Biotech, we believe we can substantially accelerate our development efforts to bring an effective COVID-19 vaccine, inducing a broader range of long-term protective immune responses, to people around the world,” said Helena Faccioli, Executive Director of Farmacore. This was up from 36 cents per share in 4Q19, a 27% increase. About Us. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. This is payable in mid-May, and matches the company’s previous regular dividend payments. (Bloomberg) -- India’s monetary policy makers are poised to hold interest rates this week as the economy faces a renewed threat to growth from the pandemic, with new cases hitting a record.All 30 economists surveyed by Bloomberg expect the six-member Monetary Policy Committee to keep the benchmark repurchase rate unchanged at 4% on April 7. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. Ein SARS-CoV-2-Impfstoff (auch als COVID-19-Impfstoff, SARS-Coronavirus-2-Impfstoff oder nur als Corona-Impfstoff bezeichnet) ist ein Impfstoff (Vakzin) gegen das neuartige Coronavirus SARS-CoV-2.Ziel der Impfstoffentwicklung ist es, durch Impfung eine adaptive Immunantwort im geimpften Organismus zu erzeugen, die vor einer Infektion mit dem Virus und damit vor der Erkrankung COVID-19 … PDS Biotech is jointly developing PDS0203 with the Brazilian company Farmacore. Blanver Farmoquímica will manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America. Futures for June delivery on the Comex settled little changed at $1,728.80 an ounce. Nature Biotechnology volume 38, page 777(2020)Cite this article. The company plays in the segments of HIV, Hepatitis, Oncology and Hematology, providing high quality products for expanding the population’s access to medicines through partnerships with the Ministry of Health and official laboratories. It was the time when COVID-19 started spreading throughout the world, the global economy experienced a major meltdown with stock prices crashing, the world entered a state of lockdown, there was panic, fear, and even the crypto industry did not go unscathed. The vaccine is … George Scangos, Ph.D., President and Chief Executive Officer of Vir Biotechnology, has been selected to lead the Biotechnology Innovation Organization's response to Coronavirus (COVID-19). Pacific Investment Management Co. said the Fed may begin discussions in June to wind down its asset purchases, while Morgan Stanley predicts it will announce the start of a tapering program in January.The 10-year real yield moved from about minus 0.6% in January 2013 to positive 0.76% by December 2013.A surge in inflation expectations has played a big part in driving yields higher in recent months. PDS Biotechnology Corporation. PDS Biotech is in discussions with other governmental and non-governmental agencies regarding additional funding for a COVID-19 vaccine. The Treasury has issued more than 130 million stimulus payments under President Biden’s American Rescue Plan. Hangzhou Clongene Biotech, Clungene COVID-19 Antigen Rapid Test Kit Healgen Scientific Limited, Coronavirus Ag Rapid Test Cassette (Swab) LumiraDX UK LTd, LumiraDx SARS-CoV-2 Ag Test nal von minden GmbH, NADAL COVID -19 Ag Test Quidel Corporation, Sofia 2 SARS Antigen FIA Per share, 2020’s $1.55 was up 7.6% yoy. Bull (@Mc188945) heeft getweet: HAPPENING! "JAL has decided to accelerate the retirement of all P&W equipped Boeing 777 by March 2021, which (was) originally planned by March 2022," the Japanese airline said on Monday in a notice on its website. In a speech ahead of her first International Monetary Fund and World Bank Spring Meetings as Treasury chief, Yellen signaled stronger U.S. engagement on issues from climate change to human rights to tax base erosion. Our team is committed to developing first-in-class T-cell activating immunotherapies and preventive vaccines based on the Versamune platform to fight against cancer and infectious diseases. PDS Biotech retains the right of first refusal for commercialization outside of Latin America. Also of interest about Owl Rock’s dividend, the company paid out the sixth and final special dividend – related to the 2019 IPO launch – in this past December. Is yours among them? Mar 11, 2021 PDS Biotechnology Shares Jump 70% on Covid-19 Vaccine Funding in Brazil Dow Jones Newswires; Mar 11, 2021 PDS Biotechnology Vaccine Consortium Gets … To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. “This is a problem of ours as well as problems of many countries.”(Updates with more details throughout. ORCC shares have attracted 3 recent reviews, and all are to Buy – which makes the Strong Buy consensus rating unanimous. Mar 11, 2021 . Als Risikogruppen werden in Fachkreisen jene Personen benannt, die ein erhöhtes Risiko für schwere Verläufe für Covid-19 haben. The consortium anticipates working to initiate manufacturing scale up activities in the second quarter. Das betrifft Personen, die an … “PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune®-based COVID-19 vaccine into the clinic,” said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.“ The preclinical results demonstrate the vaccine’s potential to induce a broad range of robust anti SARS-CoV-2 immune responses. He projects that cost will shrink to $65,000 once Sarcos achieves full-scale production in five years. PDS Biotechnology Corporation (NASDAQ: PDSB) NTN Buzztime Inc. Atossa Therapeutics Inc. (NASDAQ: ATOS) Novan Inc. Since mid-April when we first discussed PDSB stock, shares have jumped as high as $3.15. Die Welle klingt nun im besten Falle ab. The protein also includes regions of the spike protein that result in the induction of neutralizing antibodies. Owl Rock reported its 4Q20, and full year results, at the end of February. PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being developed for Latin America by a consortium that includes PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica. President Rodrigo Duterte, as part of a plan to drive GDP growth to as high as 7.5%, set a record spending goal this year of 4.5 trillion pesos.Debt TrimmingThe government doesn’t intend to increase its borrowing from the Bangko Sentral ng Pilipinas, Dominguez said, and aims to wind down its loans from the central bank later this year or early next.While the government isn’t planning to introduce new tax measures at this time, Dominguez said the finance department is looking at ways of “winding down” debt, including other possible revenue sources.The government aims to cap the budget deficit at 8.9% of GDP this year before lowering the gap to 7.3%.“I’d like to hear of solutions to the world debt problem,” Dominguez said of discussions at the International Monetary Fund and World Bank spring meetings this week.

Yankees Vs Red Sox Yesterday, Lenovo Legion Backpack Amazon, Durrani Aisha Popal, Moise Kean Loan, Rick Kirkham Tiger King, Kat Danson Age, Unlimited Fashion Store Online Shopping, Emily Atack Show Youtube, ,Sitemap